Vacaville And Visp Facilities Will Secure Future Biologics Demand

Key Takeaways

• Sustained demand and investment in advanced manufacturing are driving stable, higher-margin growth and improved operational efficiency.
  
• Divesting non-core segments and expanding globally enhance strategic focus, revenue resilience, and long-term capital allocation efficiency.
  
• Heavy reliance on unstable business segments, high expansion risks, adverse currency trends, rising competition, and divestment pressures threaten profitability, growth, and financial flexibility.

Catalysts

Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.

• Robust and sustained demand for Lonza's biologics and advanced therapy manufacturing capacity, driven by the global increase in chronic and complex diseases (notably oncology, autoimmune disorders, and new modalities like cell and gene therapies), is fueling long-term revenue growth with strong order visibility (as seen in high utilization rates and multi-year contracts), supporting top-line expansion and earnings stability.
  
• Lonza's strategic and diversified investments in cutting-edge manufacturing facilities (notably in mammalian, bioconjugate, cell & gene, and highly potent APIs) and automation upgrades (including the ongoing Vacaville and Visp expansions) are set to capture growing customer demand for next-generation therapies and support operating leverage, pointing to higher-margin growth and improved group EBITDA margins.
  
• Global pharma's ongoing shift toward outsourcing more complex manufacturing to specialized CDMOs, in tandem with increased biopharma R&D budgets, is sustaining high contract-wins, repeat business, and a diverse customer mix for Lonza, which underpins recurring revenue streams and reduces volatility in cash flow and earnings.
  
• Geographical expansion (notably in the U.S., APAC, and Europe) and Lonza's strong networked global footprint offer increased resilience-minimizing risk from localized supply chain disruptions or tariffs-while helping to drive continued customer acquisition and revenue growth from multiple major markets, supporting long-term earnings.
  
• The planned divestment of Capsules and Health Ingredients (CHI), a lower-growth, albeit cash-generative, segment, will free up capital for higher-return investments in core CDMO operations and potentially lift return on invested capital and free cash flow over the medium term, positively impacting future margins and capital allocation efficiency.

Lonza Group Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Lonza Group's revenue will grow by 11.2% annually over the next 3 years.
• Analysts assume that profit margins will increase from 15.7% today to 19.9% in 3 years time.
• Analysts expect earnings to reach CHF 1.9 billion (and earnings per share of CHF 27.05) by about July 2029, up from CHF 1.1 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as CHF1.4 billion.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 28.6x on those 2029 earnings, down from 35.4x today. This future PE is lower than the current PE for the GB Life Sciences industry at 36.5x.
• Analysts expect the number of shares outstanding to decline by 0.41% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 4.86%, as per the Simply Wall St company report.

Risks

• The Specialized Modalities business faces notable volatility due to reliance on a small pipeline of commercial Cell & Gene Therapy (CGT) products, leading to uneven asset utilization and sensitivity to clinical setbacks; this creates significant risk to both revenue stability and margins in that segment.
  
• Expansion and ramp-up of major facilities (such as Vacaville and Visp) involve high CapEx intensity and operational execution risk; delays, underutilization, or cost overruns during this expansion period could lead to higher depreciation charges and reduced return on invested capital, negatively impacting future earnings and free cash flow.
  
• Currency fluctuations, especially a strong Swiss franc against the US dollar, have created noticeable headwinds (−2.5% to −3.5% expected impact on sales and EBITDA for 2025), potentially reducing reported revenue and profit margins if the trend persists or intensifies.
  
• Increasing competition and customer negotiations in the US CDMO market could pressure pricing and limit Lonza's ability to maintain margin expansion, particularly as new customer contracts are required to offset expiring legacy contracts (e.g., Roche at Vacaville); difficulties in signing sufficient large contracts may impair revenue growth and backlog.
  
• The eventual divestment of Capsules and Health Ingredients (CHI), which is more cash-generative than the core CDMO business, may reduce the group's near-term free cash flow, while the CDMO business is still transitioning to a less CapEx-intensive, more cash-generative profile-posing a temporary risk to group-wide liquidity and financial flexibility.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of CHF677.61 for Lonza Group based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of CHF835.0, and the most bearish reporting a price target of just CHF550.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CHF9.5 billion, earnings will come to CHF1.9 billion, and it would be trading on a PE ratio of 28.6x, assuming you use a discount rate of 4.9%.
• Given the current share price of CHF548.0, the analyst price target of CHF677.61 is 19.1% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.